326 related articles for article (PubMed ID: 33800608)
1. Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment.
Terlikowska KM; Dobrzycka B; Terlikowski SJ
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800608
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
3. SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy.
Benard E; Casey NP; Inderberg EM; Wälchli S
Scand J Immunol; 2020 Oct; 92(4):e12917. PubMed ID: 32557659
[TBL] [Abstract][Full Text] [Related]
4. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer.
Leong L; Tan HL; Cua S; Yong KSM; Chen Q; Choo A
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936170
[TBL] [Abstract][Full Text] [Related]
6. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
7. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages.
Song M; Yeku OO; Rafiq S; Purdon T; Dong X; Zhu L; Zhang T; Wang H; Yu Z; Mai J; Shen H; Nixon B; Li M; Brentjens RJ; Ma X
Nat Commun; 2020 Dec; 11(1):6298. PubMed ID: 33293516
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
[TBL] [Abstract][Full Text] [Related]
10. The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells.
Hughes-Parry HE; Cross RS; Jenkins MR
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892219
[TBL] [Abstract][Full Text] [Related]
11. The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer.
Ding H; Zhang J; Zhang F; Xu Y; Yu Y; Liang W; Li Q
Med Oncol; 2022 Sep; 39(12):232. PubMed ID: 36175774
[TBL] [Abstract][Full Text] [Related]
12. Engineering strategies to optimise adoptive cell therapy in ovarian cancer.
Guerra C; Kalaitsidou M; Kueberuwa G; Hawkins R; Edmondson R
Cancer Treat Rev; 2023 Dec; 121():102632. PubMed ID: 37837788
[TBL] [Abstract][Full Text] [Related]
13. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
[TBL] [Abstract][Full Text] [Related]
14. The making and function of CAR cells.
Zabel M; Tauber PA; Pickl WF
Immunol Lett; 2019 Aug; 212():53-69. PubMed ID: 31181279
[TBL] [Abstract][Full Text] [Related]
15. Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer.
Shen Y; Liu G; Zhang Q; Tian X; Ouyang L; Zhang L
Immunol Lett; 2023 Mar; 255():1-9. PubMed ID: 36739093
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1.
Mun SS; Meyerberg J; Peraro L; Korontsvit T; Gardner T; Malviya M; Kyi C; O'Cearbhaill RE; Liu C; Dao T; Scheinberg DA
Cancer Immunol Immunother; 2023 Nov; 72(11):3773-3786. PubMed ID: 37635172
[TBL] [Abstract][Full Text] [Related]
17. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
18. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.
Koneru M; O'Cearbhaill R; Pendharkar S; Spriggs DR; Brentjens RJ
J Transl Med; 2015 Mar; 13():102. PubMed ID: 25890361
[TBL] [Abstract][Full Text] [Related]
19. Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.
Jindal V; Arora E; Gupta S; Lal A; Masab M; Potdar R
Med Oncol; 2018 Apr; 35(5):70. PubMed ID: 29651744
[TBL] [Abstract][Full Text] [Related]
20. αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib.
Fang J; Ding N; Guo X; Sun Y; Zhang Z; Xie B; Li Z; Wang H; Mao W; Lin Z; Qin F; Yuan M; Chu W; Qin H; Qian Q; Xu Q
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
